IMAPAC Glossary

Biodegradation is the natural breakdown of materials by microorganisms into simpler compounds within the environment.

A bioenhancer is a substance that improves the absorption, bioavailability or therapeutic effectiveness of another drug without having significant activity itself.

A bioequivalence study compares two pharmaceutical products to demonstrate that they deliver the same therapeutic performance in the body.

A biohazard is any biological material that poses a potential risk to human health, animals or the environment.

Bioinformatics in drug target identification uses computational analysis of biological datasets to discover, prioritise and validate disease-associated therapeutic targets.

Biological assay variability is the natural variation observed in biological test results due to biological systems, analytical methods or experimental conditions.

Biological half-life is the time required for the amount of a drug or biological substance in the body to decrease by half through biological processes.

Biological product comparability demonstrates that manufacturing changes have not adversely affected a biologic�s quality, safety or efficacy.

A Biologic Licence Application (BLA) is a regulatory submission requesting approval to market a biological product based on evidence of quality, safety and efficacy.

Bioluminescence Resonance Energy Transfer (BRET) is a molecular technique that measures protein interactions by transferring energy from a bioluminescent donor to a fluorescent acceptor.

Biomarker assay validation demonstrates that an analytical method reliably measures a biomarker with suitable accuracy, precision, sensitivity, specificity and reproducibility.

Biomass monitoring measures the concentration and growth of cells or microorganisms during bioprocessing to optimise productivity and process performance.

Bio-orthogonal chemistry comprises selective chemical reactions that occur within biological environments without interfering with native cellular processes.

Biopharmaceutical supply chain resilience is the ability to anticipate, withstand and recover from disruptions while maintaining the supply of critical medicines.

A biopharma cold chain is the temperature-controlled storage and distribution network that preserves the quality, stability and efficacy of temperature-sensitive biological products.

Biopharma outsourcing is the use of external organisations to perform pharmaceutical development, manufacturing, analytical or support activities on behalf of sponsors.

Biophysical characterisation evaluates the physical and structural properties of biological molecules to confirm their identity, stability and functional integrity.

Bioprocess development is the optimisation of upstream and downstream manufacturing processes to produce safe, high-quality biopharmaceutical products.

Bioprocess intensification increases manufacturing productivity and efficiency by integrating operations, increasing cell density or reducing equipment, time and facility requirements.

A bioreactor is a controlled vessel that provides optimal conditions for growing cells or microorganisms to manufacture biological products.

Bioreactor fouling is the unwanted accumulation of biological or chemical material on reactor surfaces that reduces process efficiency and manufacturing performance.

Biosensor technology combines biological recognition elements with analytical detectors to rapidly identify or quantify specific biological or chemical targets.

A biosimilar is a biological medicine demonstrated to be highly similar to an approved reference product with no clinically meaningful differences.

A biosimilar development strategy defines the scientific, clinical, regulatory and manufacturing approach used to demonstrate high similarity to an approved reference biologic.

Biostability is the ability of a biological product to maintain its structural integrity, activity and quality throughout storage, handling and clinical use.

The biotin-streptavidin system uses an exceptionally strong non-covalent interaction to support biomolecule capture, detection, purification and targeted delivery.

Biotransformation is the enzymatic conversion of drugs or other compounds into metabolites that influence their activity, toxicity and elimination.

Biovigilance is the ongoing monitoring of biological products to detect, assess and manage safety risks throughout their lifecycle.

Biowaivers are regulatory exemptions allowing certain bioequivalence studies to be omitted when pharmaceutical equivalence and suitable in vitro evidence are demonstrated.

Bispecific antibody formats are engineered antibody structures capable of binding two different antigens or epitopes simultaneously to produce combined therapeutic effects.

Blinding procedures are clinical trial methods that conceal treatment allocation to minimise bias during study conduct, assessment and data interpretation.

Blood-brain barrier modelling uses experimental or computational systems to replicate the barrier between the bloodstream and the brain for research and drug development.

Blood cell therapy uses living blood-derived cells to treat disease by restoring, replacing or modifying normal biological functions.

The bone marrow microenvironment is the specialised cellular and structural niche that regulates blood cell formation, stem cell maintenance and immune function.

Bottleneck analysis identifies process constraints that limit manufacturing efficiency, productivity or throughput to support targeted process improvement.

Branched-chain fatty acids are fatty acids containing branched carbon chains that influence membrane properties, metabolism and microbial physiology.

Breakthrough Therapy Designation is an FDA programme that expedites the development and review of treatments showing substantial improvement for serious conditions.

A bridging study evaluates whether existing clinical or analytical data can support a new population, formulation, manufacturing process or regulatory region.

Buffer exchange replaces one buffer system with another while retaining the target biomolecule, typically to support purification, formulation or analytical testing.

Buffer preparation is the process of formulating solutions that maintain stable pH conditions during biopharmaceutical manufacturing and analytical testing.

Bulk drug substance is the manufactured active pharmaceutical ingredient held before final formulation, filling, packaging and release as a finished drug product.

Bundling strategy in market access combines multiple products, services or agreements into a single commercial offering to support pricing, reimbursement or procurement objectives.

Buoyancy effects in centrifugation describe how differences between particle and fluid density influence sedimentation speed, separation efficiency and equilibrium position.

The bystander effect occurs when nearby cells are affected by a therapy despite not directly expressing or encountering its intended molecular target.

Capillary Electrophoresis is a high-resolution analytical technique that separates charged biomolecules within a capillary to characterise biologics, detect impurities and assess product heterogeneity.

Capsid engineering modifies the protein shell of viral vectors to improve tissue targeting, transduction efficiency, immune evasion or manufacturing performance.

Carcinogenicity assessment evaluates whether prolonged exposure to a pharmaceutical product may cause or increase the risk of cancer.

A carrier protein is an immunogenic protein chemically linked to weak antigens to enhance immune responses in conjugate vaccines.

CAR-T Therapy is a personalised cell therapy that engineers a patient's T cells to recognise and destroy cancer cells.

A Case Report Form (CRF) is a standardised document used to accurately record protocol-required data for each participant in a clinical trial.

A cell bank is a qualified collection of characterised cells preserved under controlled conditions to provide a consistent and traceable source for biopharmaceutical manufacturing.

Cell banking is the process of establishing, testing and storing qualified cell banks to ensure a reliable, traceable and consistent source of production cells.

Cell banking strategy encompasses the establishment, qualification, storage and lifecycle management of master and working cell banks for consistent manufacturing.

A cell-based assay measures the biological activity, potency or safety of a product by evaluating its effects on living cells.

Cell culture is the controlled growth and maintenance of cells outside the body for research, therapeutic development and biopharmaceutical manufacturing.

A cell-free system is an experimental platform that performs biological reactions using cellular components without requiring living cells.

Cell fusion is the combination of two or more cells into a single hybrid cell to obtain new biological characteristics or functions.

Cell proliferation is the process by which cells grow and divide to increase cell numbers during normal biological function or manufacturing.

Cell sorting is the isolation of specific cell populations based on defined physical or biological characteristics using specialised separation technologies.

A central laboratory is a designated facility that performs standardised testing for multi-site clinical trials to ensure consistent and comparable analytical results.

Chain of custody is the documented process that tracks the handling, transfer and storage of materials or samples to maintain their identity and integrity.

Change control is a documented quality process used to evaluate, approve and implement changes that may affect pharmaceutical products, processes or systems.

A charge variant is a molecular form of a protein that differs in electrical charge due to chemical or post-translational modifications.

A checkpoint inhibitor blocks immune-regulatory proteins that restrain T-cell activity, enabling stronger immune responses against cancer or other disease targets.

Chemistry, Manufacturing and Controls (CMC) comprises the processes, controls and regulatory documentation that demonstrate a pharmaceutical product can be consistently manufactured to the required quality.

Chromatin accessibility describes how open or compact genomic DNA is, determining whether regulatory proteins can reach genes and influence their expression.

A cleanroom is a controlled manufacturing environment designed to minimise airborne particles, microorganisms and other sources of contamination.

Clearance is the biological process by which a drug or therapeutic substance is removed from the body through metabolism or excretion.

A clinical batch record documents the materials, manufacturing steps, controls, deviations and test results associated with producing a clinical trial batch.

Cohort event monitoring prospectively follows defined groups of treated patients to identify, characterise and quantify adverse events during real-world medicine use.

A combination product integrates a drug, biologic and/or medical device into a single therapeutic product regulated as one medical solution.

Conditional Approval is a regulatory pathway that permits earlier access to promising therapies for serious conditions while additional confirmatory evidence is generated after approval.

A continuous manufacturing process produces pharmaceutical products through an uninterrupted sequence of integrated manufacturing steps, improving efficiency and product consistency.

A contraindication review evaluates situations or patient characteristics in which a medicine should not be used because the risks outweigh the potential benefits.

A crystalline polymorph is a distinct crystal structure of the same chemical substance that can influence its stability, solubility, manufacturability and bioavailability.

A cytokine release assay measures cytokine production following immune cell activation to evaluate immunogenicity, potency or the risk of cytokine release syndrome.

A data harmonisation standard establishes consistent formats and definitions for integrating data from multiple sources to improve quality and interoperability.

Data integrity is the assurance that data remain complete, accurate, consistent and reliable throughout their entire lifecycle.

Data integrity compliance ensures that records remain complete, accurate, consistent and attributable throughout their lifecycle in accordance with regulatory requirements.

Data migration risk assessment identifies and evaluates risks associated with transferring regulated data between systems while maintaining integrity and traceability.

A deamidation mechanism describes the chemical conversion of amino acid residues that can alter protein stability, structure and biological activity.

A decoy receptor is a receptor that binds signalling molecules without triggering a biological response, thereby blocking their normal activity.

Degradation byproduct characterisation identifies and evaluates compounds formed during product degradation to ensure pharmaceutical quality and patient safety.

Degradation kinetics quantitation measures the rate and extent of pharmaceutical product degradation under defined environmental or storage conditions.

Delivery rate prediction estimates the speed at which a therapeutic product is released or administered under defined conditions.

Delivery system performance validation demonstrates that a drug delivery system consistently performs according to predefined functional and quality requirements.

A demand forecasting model predicts future product demand using historical data, market trends and analytical methods to support supply planning.

Demographic variation assessment evaluates differences in therapeutic response, safety or disease characteristics across defined population groups.

Demonstrated clinical activity refers to evidence showing that an investigational therapy produces meaningful therapeutic effects in patients.

Depot formulation bioavailability evaluates the absorption and systemic availability of medicines designed for sustained or controlled release after administration.

Dermal irritation potential assesses the likelihood that a substance will cause reversible skin irritation following topical exposure.

Design of Experiments (DOE) is a structured statistical approach used to optimise processes by evaluating the effects of multiple variables simultaneously.

A design space definition describes the multidimensional range of process parameters and material attributes proven to consistently deliver products of the required quality.

Detection assay selectivity demonstrates that an analytical method accurately measures the intended analyte without interference from other sample components.

Detection limit determination establishes the lowest concentration of an analyte that can be reliably detected by an analytical method.

A deviation is any unplanned departure from an approved procedure, specification or quality requirement that must be investigated and documented.

Device biocompatibility assessment evaluates whether a medical device performs safely without causing unacceptable biological or toxicological responses.

A device-drug combination integrates a medical device with a pharmaceutical product to achieve a combined therapeutic effect.

Dialysate formulation is the preparation of dialysis fluid with precisely controlled electrolyte and chemical composition to support safe and effective dialysis treatment.

Dialysis clearance prediction estimates the extent to which a substance will be removed during dialysis to support dosing decisions in patients with impaired kidney function.